---
title: Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene
  Ciloleucel
date: '2025-01-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39883946/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250131170625&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel
  (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)
  are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging
  evidence indicates that delayed CAR T-cell infusion, including prolonged time from
  leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact
  clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis
  to ...
disable_comments: true
---
Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to ...